Certificate of Analysis
Independent laboratory testing confirms purity and composition of this research peptide.
Overview
CJC-1295 (No DAC), more accurately described as Modified GRF(1-29), is a short-acting GHRH analog designed to stimulate the pituitary growth-hormone pathway. Its four amino-acid substitutions improve resistance to enzymatic degradation while leaving out the albumin-binding DAC extension used in long-acting CJC-1295.
Research Reference: View compound profile on NIH PubChem
Research Focus
WHAT THIS FORMULA FEATURES
A stabilized 29-residue GHRH scaffold that keeps the research focus on pulse-like GH release rather than multi-day exposure. Direct controlled human data for the no-DAC variant are limited, so its expected behavior is largely inferred from GHRH(1-29) pharmacology and the better-characterized DAC form.
EXPECTED RESEARCH READOUTS
Common endpoints are GH release or pulse amplitude, GH area-under-the-curve, downstream IGF-1, pituitary GHRH-receptor signaling, and time-course comparisons versus native GHRH or DAC-CJC controls. The short-acting profile is a key experimental distinction.
Research endpoints described above reflect published or model-based scientific observations and are not guaranteed outcomes. This product is strictly for research purposes only. Not approved for human or animal use.
